Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteocytes | 3 | 2014 | 18 | 1.090 |
Why?
|
| Femur | 11 | 2015 | 298 | 0.710 |
Why?
|
| Vitallium | 2 | 2011 | 21 | 0.640 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2011 | 163 | 0.610 |
Why?
|
| Ultrasonic Therapy | 4 | 2014 | 21 | 0.600 |
Why?
|
| Prostheses and Implants | 5 | 2014 | 132 | 0.570 |
Why?
|
| Osteogenesis | 8 | 2015 | 99 | 0.550 |
Why?
|
| Transforming Growth Factor beta | 4 | 2014 | 82 | 0.520 |
Why?
|
| Rats | 16 | 2015 | 623 | 0.500 |
Why?
|
| Animals | 21 | 2015 | 3270 | 0.500 |
Why?
|
| Rats, Sprague-Dawley | 15 | 2015 | 314 | 0.460 |
Why?
|
| Bone Morphogenetic Proteins | 3 | 2015 | 64 | 0.450 |
Why?
|
| Titanium | 4 | 2014 | 139 | 0.450 |
Why?
|
| Nickel | 1 | 2014 | 20 | 0.440 |
Why?
|
| Cobalt | 1 | 2014 | 71 | 0.420 |
Why?
|
| Bone Marrow Cells | 3 | 2010 | 49 | 0.390 |
Why?
|
| Bone Regeneration | 5 | 2015 | 67 | 0.360 |
Why?
|
| NFATC Transcription Factors | 1 | 2011 | 9 | 0.350 |
Why?
|
| Calcineurin | 1 | 2011 | 8 | 0.350 |
Why?
|
| Gap Junctions | 1 | 2011 | 11 | 0.340 |
Why?
|
| Cell Communication | 1 | 2011 | 21 | 0.340 |
Why?
|
| Stromal Cells | 2 | 2010 | 33 | 0.330 |
Why?
|
| Signal Transduction | 3 | 2012 | 387 | 0.330 |
Why?
|
| Osteoblasts | 3 | 2015 | 52 | 0.310 |
Why?
|
| Gene Expression | 2 | 2011 | 178 | 0.300 |
Why?
|
| Bone Remodeling | 3 | 2014 | 48 | 0.290 |
Why?
|
| Bone Morphogenetic Protein 2 | 3 | 2014 | 43 | 0.270 |
Why?
|
| Inflammation | 1 | 2009 | 227 | 0.270 |
Why?
|
| Prosthesis Failure | 4 | 2015 | 414 | 0.260 |
Why?
|
| Cell Line | 3 | 2014 | 242 | 0.260 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 68 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2014 | 313 | 0.240 |
Why?
|
| Antibodies | 3 | 2015 | 43 | 0.230 |
Why?
|
| Ultrasonics | 1 | 2005 | 10 | 0.230 |
Why?
|
| Cells, Cultured | 5 | 2011 | 462 | 0.220 |
Why?
|
| Bone Resorption | 4 | 2015 | 75 | 0.220 |
Why?
|
| Bone Marrow | 3 | 2015 | 61 | 0.210 |
Why?
|
| Osseointegration | 2 | 2015 | 69 | 0.200 |
Why?
|
| Osteoporosis | 2 | 2015 | 73 | 0.190 |
Why?
|
| Mice | 4 | 2015 | 1238 | 0.180 |
Why?
|
| Biomarkers | 2 | 2014 | 474 | 0.160 |
Why?
|
| Recombinant Proteins | 4 | 2014 | 161 | 0.150 |
Why?
|
| Cell Differentiation | 2 | 2010 | 124 | 0.140 |
Why?
|
| Male | 13 | 2014 | 12460 | 0.140 |
Why?
|
| X-Ray Microtomography | 6 | 2014 | 74 | 0.140 |
Why?
|
| Microscopy, Fluorescence | 2 | 2014 | 69 | 0.140 |
Why?
|
| Models, Animal | 6 | 2014 | 103 | 0.130 |
Why?
|
| Bone and Bones | 2 | 2015 | 107 | 0.130 |
Why?
|
| Genetic Markers | 2 | 2015 | 30 | 0.120 |
Why?
|
| Materials Testing | 3 | 2012 | 102 | 0.120 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2014 | 5 | 0.110 |
Why?
|
| Molybdenum | 1 | 2014 | 15 | 0.110 |
Why?
|
| Cell Death | 1 | 2014 | 34 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 73 | 0.110 |
Why?
|
| Chromium | 1 | 2014 | 56 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 45 | 0.110 |
Why?
|
| Bone Matrix | 1 | 2014 | 18 | 0.110 |
Why?
|
| Glycoproteins | 1 | 2014 | 41 | 0.110 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 175 | 0.100 |
Why?
|
| Osteolysis | 1 | 2014 | 113 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2012 | 3 | 0.100 |
Why?
|
| Adult Stem Cells | 1 | 2012 | 3 | 0.100 |
Why?
|
| Heterocyclic Compounds | 1 | 2012 | 6 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 226 | 0.090 |
Why?
|
| Prosthesis Implantation | 1 | 2012 | 25 | 0.090 |
Why?
|
| Cell Movement | 1 | 2012 | 77 | 0.090 |
Why?
|
| Polyethylene | 1 | 2012 | 93 | 0.090 |
Why?
|
| Fracture Healing | 1 | 2012 | 31 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 164 | 0.090 |
Why?
|
| Calcineurin Inhibitors | 1 | 2011 | 15 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2011 | 70 | 0.090 |
Why?
|
| Disease Models, Animal | 4 | 2015 | 526 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2011 | 109 | 0.080 |
Why?
|
| Radiation Dosage | 1 | 2011 | 35 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 104 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 108 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2009 | 70 | 0.070 |
Why?
|
| Apoptosis | 1 | 2009 | 194 | 0.070 |
Why?
|
| Dactinomycin | 1 | 2007 | 6 | 0.060 |
Why?
|
| Cycloheximide | 1 | 2007 | 7 | 0.060 |
Why?
|
| Growth Differentiation Factor 5 | 1 | 2007 | 6 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 9 | 0.060 |
Why?
|
| Guided Tissue Regeneration | 1 | 2006 | 8 | 0.060 |
Why?
|
| Biomimetic Materials | 1 | 2006 | 6 | 0.060 |
Why?
|
| Extracellular Matrix | 1 | 2006 | 49 | 0.060 |
Why?
|
| Femoral Fractures | 1 | 2006 | 30 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2007 | 144 | 0.060 |
Why?
|
| Genes, jun | 1 | 2005 | 4 | 0.060 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2005 | 5 | 0.060 |
Why?
|
| Osteonectin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 7 | 0.060 |
Why?
|
| Immediate-Early Proteins | 1 | 2005 | 5 | 0.060 |
Why?
|
| Osteopontin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Genes, myc | 1 | 2005 | 8 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 23 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 29 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2005 | 33 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 131 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2005 | 148 | 0.050 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2011 | 686 | 0.050 |
Why?
|
| Regeneration | 2 | 2015 | 15 | 0.050 |
Why?
|
| Ovariectomy | 2 | 2015 | 26 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 228 | 0.050 |
Why?
|
| Random Allocation | 2 | 2012 | 102 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 363 | 0.050 |
Why?
|
| Wnt Proteins | 2 | 2012 | 21 | 0.040 |
Why?
|
| Bone Density | 2 | 2014 | 146 | 0.040 |
Why?
|
| Female | 4 | 2015 | 12958 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2015 | 16 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2015 | 31 | 0.030 |
Why?
|
| Species Specificity | 1 | 2015 | 34 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 90 | 0.030 |
Why?
|
| Humans | 2 | 2012 | 22932 | 0.030 |
Why?
|
| Diaphyses | 1 | 2014 | 5 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 31 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2014 | 25 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 260 | 0.030 |
Why?
|
| Humerus | 1 | 2014 | 89 | 0.030 |
Why?
|
| Periosteum | 1 | 2012 | 4 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2012 | 5 | 0.020 |
Why?
|
| Benzylamines | 1 | 2012 | 12 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2012 | 10 | 0.020 |
Why?
|
| Tensile Strength | 1 | 2012 | 20 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2012 | 17 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 100 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 153 | 0.020 |
Why?
|
| Tibia | 1 | 2014 | 197 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 169 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2012 | 57 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 592 | 0.020 |
Why?
|
| Collagen | 1 | 2012 | 81 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 163 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 521 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 370 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 9 | 0.020 |
Why?
|
| Transducers | 1 | 2010 | 10 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2010 | 17 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 18 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2012 | 536 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 54 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2010 | 32 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 104 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 132 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 130 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 120 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 548 | 0.020 |
Why?
|
| Rats, Long-Evans | 1 | 2009 | 10 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 577 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2014 | 354 | 0.020 |
Why?
|
| Ossification, Heterotopic | 1 | 2009 | 32 | 0.020 |
Why?
|
| Time Factors | 1 | 2012 | 1261 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 295 | 0.020 |
Why?
|
| Biomimetics | 1 | 2006 | 6 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2006 | 21 | 0.020 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2006 | 21 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2006 | 24 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2012 | 2941 | 0.010 |
Why?
|